Antioxidants, Oxidative Damage and Inflammation in Obese Subjects without Type-2 Diabetes Mellitus and Age and Gender Matched Obese Subjects with Type-2 Diabetes

Prevalence of type 2 diabetes mellitus (DM) tends to increasing worldwide. The main cause of death in type 2 DM is coronaryheart disease (CHD) and its mortality rate can increase 2 to 4 times compared to non-diabetics. One of the risk factors in CHD isdyslipidemia. To know the lipid profile based on age and gender and to assess the relation of total cholesterol, LDL, HDL, and TG levelto age. Descriptive retrospective study in patients with type 2 DM who are 45 years old and over. From 100 Type 2 DM patients, in theDepartment of Internal Medicine, Dr. Wahidin Sudirohusodo Hospital, Makassar, period of June to December 2005, the largest age groupwith dyslipidemia was > 59 years old, with increase LDL level, 32.73% in males and 46.67% in females. There was a significant relationbetween the in crease of TG (p = 0.03) and the decrease of HDL (p = 0.02) with age. Dyslipidemia in type 2 DM patients at age group> 59 years old was shown by an increase in LDL level. The increase of TG and decrease of HDL level were significant in all age groups.Restriction of this study was not to check the antilipidemic medicine used. Early dyslipidemia of Type 2 DM should be known by lipidfraction determination and further dyslipidemia study should be conducted to predict the risk of CHD.

Download Full-text

Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up

European Psychiatry ◽

10.1016/j.eurpsy.2011.02.009 ◽

2012 ◽

Vol 27 (1) ◽

pp. 33-42 ◽

Cited By ~ 47

Author(s):

D. Schoepf ◽

R. Potluri ◽

H. Uppal ◽

A. Natalwala ◽

P. Narendran ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Excess Mortality ◽

Age And Gender ◽

Predictors Of Mortality ◽

Co Morbidity ◽

And Gender ◽

The Impact

AbstractObjectivePhysical co-morbidity including type 2 diabetes mellitus is more prevalent in patients with schizophrenia compared to the general population. However, there is little consistent evidence that co-morbidity with diabetes mellitus and/or other diseases leads to excess mortality in schizophrenia. Thus, we investigated whether co-morbidity with diabetes and other somatic diseases is increased in schizophrenics, and if these are equally or more relevant predictors of mortality in schizophrenia than in age- and gender-matched hospitalised controls.MethodsDuring 2000–2007, 679 patients with schizophrenia were admitted to University Hospital Birmingham NHS Trust. Co-morbidities were compared with 88,778 age- and gender group-matched hospital controls. Predictors of mortality were identified using forward Cox regression models.ResultsThe prevalence of type 2 diabetes mellitus was increased in schizophrenia compared to hospitalised controls (11.3% versus 6.3%). The initial prevalence of type 2 diabetes mellitus was significantly higher in the 100 later deceased schizophrenic patients (24.0%) than in those 579 surviving over 7 years (9.2%). Predictors of mortality in schizophrenia were found to be age (relative risk [RR] = 1.1/year), type 2 diabetes mellitus (RR = 2.2), pneumonia (RR = 2.7), heart failure (RR = 2.9) and chronic renal failure (RR = 3.2). The impact of diabetes mellitus on mortality was significantly higher in schizophrenia than in hospital controls (RR = 2.2 versus RR = 1.1). In agreement, deceased schizophrenics had significantly suffered more diabetes mellitus than deceased controls (24.0 versus 10.5%). The relative risks of mortality for other disorders and their prevalence in later deceased subjects did not significantly differ between schizophrenia and controls.ConclusionSchizophrenics have more and additionally suffer more from diabetes: co-morbidity with diabetes mellitus is increased in schizophrenia in comparison with hospital controls; type 2 diabetes mellitus causes significant excess mortality in schizophrenia. Thus, monitoring for and prevention of type 2 diabetes mellitus is of utmost relevance in hospitalised patients with schizophrenia.

Download Full-text

Impact on Diabetes Mellitus on the Epicardial Coronary Flow Velocity Assessed by the Thrombolysis in Myocardial Infarction Frame Count

Angiology ◽

10.1177/0003319708321187 ◽

2008 ◽

Vol 60 (4) ◽

pp. 431-440 ◽

Cited By ~ 1

Author(s):

Ahmet Soylu ◽

Kurtulus Ozdemir ◽

Mehmet Akif Duzenli ◽

Mehmet Yazici ◽

Mehmet Tokac

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Flow Velocity ◽

Coronary Arteries ◽

Coronary Flow ◽

Coronary Flow Velocity ◽

And Gender

The aim of this study is to evaluate the effect of type 2 diabetes mellitus on epicardial coronary flow velocity assessed by the thrombolysis in myocardial infarction frame count. The thrombolysis in myocardial infarction frame count was measured in 272 coronary arteries from 101 patients with type 2 diabetes mellitus and in 271 coronary arteries from 104 age- and gender-matched patients without type 2 diabetes mellitus referred for coronary angiography. The thrombolysis in myocardial infarction frame count was measured only in normal arteries or in arteries without significant lesion. By both univariate and multivariate analysis, the thrombolysis in myocardial infarction frame count was not related with either type 2 diabetes mellitus or the duration and glycated hemoglobin levels in the patients with type 2 diabetes mellitus. The thrombolysis in myocardial infarction frame count was significantly associated with body surface area, heart rate, and proximal coronary artery diameter. Type 2 diabetes mellitus did not affect epicardial coronary flow velocity assessed by the thrombolysis in myocardial infarction frame count.

Download Full-text

Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus

Clinica Chimica Acta ◽

10.1016/j.cca.2017.11.023 ◽

2018 ◽

Vol 476 ◽

pp. 98-102 ◽

Cited By ~ 4

Author(s):

Zhong-wei Zhou ◽

Hui-xiang Ju ◽

Ming-zhong Sun ◽

Hong-mei Chen ◽

Qing-ping Fu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fetuin A ◽

Obese Subjects

Download Full-text

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus

Antioxidants ◽

10.3390/antiox9030233 ◽

2020 ◽

Vol 9 (3) ◽

pp. 233

Author(s):

Elisabetta Bigagli ◽

Cristina Luceri ◽

Ilaria Dicembrini ◽

Lorenzo Tatti ◽

Francesca Scavone ◽

...

Keyword(s):

Oxidative Stress ◽

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Propensity Score ◽

Oxidative Damage ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors

Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl peptidase-4 inhibitors (DPP4i), however, clinical trials showed neither beneficial nor detrimental effects in patients with type 2 diabetes mellitus (T2DM). We examined the effects of DPP4i on several circulating oxidative stress markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal females), who were already on routine antidiabetic treatment. Propensity score matching was used to adjust demographic and clinical characteristics between patients who received and who did not receive DPP4i. Whole-blood reactive oxygen species (ROS), plasma advanced glycation end products (AGEs), advanced oxidation protein products (AOPP), carbonyl residues, as well as ferric reducing ability of plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. With the exception of Fpg sites, that showed a borderline increase in DPP4i users compared to non-users (p = 0.0507), none of the biomarkers measured was affected by DPP4i treatment. An inverse correlation between estimated glomerular filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed. This study does not show any major effect of DPP4i on oxidative stress, assessed by several circulating biomarkers of oxidative damage, in propensity score-matched cohorts of T2DM patients.

Download Full-text